Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...
(CNN) — Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback